Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.

In this study, 54 of 174 (31%) of participants with peri-HCT MRD had ≥2 FLT3-ITD mutations, and the presence of this multiclonality was associated with a worse RFS irrespective of treatment arm when compared with all other participants on the trial and when compared with participants with MRD consisting of just a single FLT3-ITD clone, although that difference did not reach statistical significance ( Figure 6 ; supplemental Figures 11 and 12 ).

also in 111,027 other papers